> Back to EJC

2016 editions

  • December 2016
    Joao Incio on mechanisms to explain why obesity promotes cancer.
  • November 2016
    Mike Stratton on how mutational changes in a cancer genome can point to the cause of the cancer.
  • October 2016
    Ruth Muschel on a new target for treatments for colorectal cancer.
  • September 2016
    Freddie Hamdy on the effectiveness of treatments for prostate cancer.
  • August 2016
    Moshe Oren discusses the effects of the microenvironment on cancer cells.
  • July 2016
    Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
  • June 2016
    Key advances in clinical trials.
  • May 2016
    Mark Lemmon on the underlying biochemistry of cancer.
  • April 2016
    Roger Stupp on using alternating electric fields as treatment.
  • March 2016
    Charlotte Vrinten on public perception of deaths from cancer.
  • February 2016
    Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
  • December 2015/January 2016
    Nazneen Rahman on germline genetic screening in ovarian cancer.

> All 2015 Editions

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – September 2013

Loading EJC News Focus video

EJC's Drug of the Year, 2013

Immunotherapy is finally emerged from the shadows as a realistic – and perhaps essential – tool in cancer control. After decades of painstaking research which yielded little benefit for patients, immunotherapy has entered a fresh phase with the development of new agents that can either activate the immune system or re-awaken silenced immune responses to a tumour.

The emerging paradigm, by which only the most effective immune cells are selectively harnessed to target the tumour, is an immediate advance for patients. It also holds the promise of future steps forward, as clinicians and researchers learn how best to use the new agents in combination.

In this month's EJC News Focus, Jean-Charles Soria and Caroline Robert, both from Institut Gustave Roussy, Paris-Sud, France, explain to Helen Saul why the Programmed Death-1 receptor (PD-1), and its ligand (PD-L1), have been recognised in EJC's Drug of the Year article, 2013.